(Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to $1.7B to jointly develop and commercialize LEO’s anti-inflammatory drugs ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for upward estimate revisions on lenacapavir forpre ...

Gilead Sciences (GILD) ended the recent trading session at $89.14, demonstrating a -1.64% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

(Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be ...